Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline)

D. L. Murphy, F. Karoum, D. Pickar, R. M. Cohen, S. Lipper, A. M. Mellow, P. N. Tariot, T. Sunderland

Research output: Contribution to journalArticle

Abstract

Marked, dose-dependent elevation in the urinary excretion of phenylethylamine, para-tyramine, and meta-tyramine were observed in depressed patients treated for three or more weeks with 10, 30, or 60mg/day of the partially-selective inhibitor of MAO-B, selegiline (l-deprenyl). In comparative studies with other, structurally similar acetylenic inhibitors of MAO, pargyline, an MAO-B > MAO-A inhibitor used in doses of 90mg/day for three or more weeks, produced elevations in these trace amines which were similar to those found with the highest dose of selegiline studied. Clorgyline, a selective inhibitor of MAO-A used in doses of 30mg/day for three or more weeks (a dose-time regimen previously reported to reduce urinary, plasma, and cerebrospinal fluid 3-methoxy-4- hydroxyphenylethyleneglycol (MHPG) > 80%, indicating a marked inhibitory effect on MAO-A in humans in vivo) produced negligible changes in trace amine excretion. In comparison to recent studies of individuals lacking the genes for MAO-A, MAO-B, or both MAO-A and MAO-B, the lack of change in trace amine excretion in individuals with a mutation affecting only MAO-A is in agreement with the observed lack of effect of clorgyline in the present study. Selegiline produced larger changes in trace amines-at least at the higher doses studied-than found in individuals lacking the gene for MAO-B, in agreement with other data suggesting a lesser selectivity for MAO-B inhibition when selegiline was given in doses higher than 10mg/day. Overall, trace amine elevations in individuals receiving the highest dose of deprenyl or receiving pargyline were approximately three to five-fold lower than the elevations observed in individuals lacking the genes for both MAO-A and MAO- B, suggesting that these drug doses yield incomplete inhibition of MAO-A and MAO-B.

Original languageEnglish (US)
Pages (from-to)39-48
Number of pages10
JournalJournal of Neural Transmission, Supplement
Issue number52
StatePublished - 1998
Externally publishedYes

Fingerprint

Clorgyline
Pargyline
Selegiline
Monoamine Oxidase
Amines
Monoamine Oxidase Inhibitors
Genes
Phenethylamines
Tyramine

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Murphy, D. L., Karoum, F., Pickar, D., Cohen, R. M., Lipper, S., Mellow, A. M., ... Sunderland, T. (1998). Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). Journal of Neural Transmission, Supplement, (52), 39-48.

Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). / Murphy, D. L.; Karoum, F.; Pickar, D.; Cohen, R. M.; Lipper, S.; Mellow, A. M.; Tariot, P. N.; Sunderland, T.

In: Journal of Neural Transmission, Supplement, No. 52, 1998, p. 39-48.

Research output: Contribution to journalArticle

Murphy, DL, Karoum, F, Pickar, D, Cohen, RM, Lipper, S, Mellow, AM, Tariot, PN & Sunderland, T 1998, 'Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline)', Journal of Neural Transmission, Supplement, no. 52, pp. 39-48.
Murphy, D. L. ; Karoum, F. ; Pickar, D. ; Cohen, R. M. ; Lipper, S. ; Mellow, A. M. ; Tariot, P. N. ; Sunderland, T. / Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline). In: Journal of Neural Transmission, Supplement. 1998 ; No. 52. pp. 39-48.
@article{38460a8924144957bf34e93cedecf4a9,
title = "Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline)",
abstract = "Marked, dose-dependent elevation in the urinary excretion of phenylethylamine, para-tyramine, and meta-tyramine were observed in depressed patients treated for three or more weeks with 10, 30, or 60mg/day of the partially-selective inhibitor of MAO-B, selegiline (l-deprenyl). In comparative studies with other, structurally similar acetylenic inhibitors of MAO, pargyline, an MAO-B > MAO-A inhibitor used in doses of 90mg/day for three or more weeks, produced elevations in these trace amines which were similar to those found with the highest dose of selegiline studied. Clorgyline, a selective inhibitor of MAO-A used in doses of 30mg/day for three or more weeks (a dose-time regimen previously reported to reduce urinary, plasma, and cerebrospinal fluid 3-methoxy-4- hydroxyphenylethyleneglycol (MHPG) > 80{\%}, indicating a marked inhibitory effect on MAO-A in humans in vivo) produced negligible changes in trace amine excretion. In comparison to recent studies of individuals lacking the genes for MAO-A, MAO-B, or both MAO-A and MAO-B, the lack of change in trace amine excretion in individuals with a mutation affecting only MAO-A is in agreement with the observed lack of effect of clorgyline in the present study. Selegiline produced larger changes in trace amines-at least at the higher doses studied-than found in individuals lacking the gene for MAO-B, in agreement with other data suggesting a lesser selectivity for MAO-B inhibition when selegiline was given in doses higher than 10mg/day. Overall, trace amine elevations in individuals receiving the highest dose of deprenyl or receiving pargyline were approximately three to five-fold lower than the elevations observed in individuals lacking the genes for both MAO-A and MAO- B, suggesting that these drug doses yield incomplete inhibition of MAO-A and MAO-B.",
author = "Murphy, {D. L.} and F. Karoum and D. Pickar and Cohen, {R. M.} and S. Lipper and Mellow, {A. M.} and Tariot, {P. N.} and T. Sunderland",
year = "1998",
language = "English (US)",
pages = "39--48",
journal = "Journal of Neural Transmission, Supplement",
issn = "0303-6995",
publisher = "Springer Wien",
number = "52",

}

TY - JOUR

T1 - Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline)

AU - Murphy, D. L.

AU - Karoum, F.

AU - Pickar, D.

AU - Cohen, R. M.

AU - Lipper, S.

AU - Mellow, A. M.

AU - Tariot, P. N.

AU - Sunderland, T.

PY - 1998

Y1 - 1998

N2 - Marked, dose-dependent elevation in the urinary excretion of phenylethylamine, para-tyramine, and meta-tyramine were observed in depressed patients treated for three or more weeks with 10, 30, or 60mg/day of the partially-selective inhibitor of MAO-B, selegiline (l-deprenyl). In comparative studies with other, structurally similar acetylenic inhibitors of MAO, pargyline, an MAO-B > MAO-A inhibitor used in doses of 90mg/day for three or more weeks, produced elevations in these trace amines which were similar to those found with the highest dose of selegiline studied. Clorgyline, a selective inhibitor of MAO-A used in doses of 30mg/day for three or more weeks (a dose-time regimen previously reported to reduce urinary, plasma, and cerebrospinal fluid 3-methoxy-4- hydroxyphenylethyleneglycol (MHPG) > 80%, indicating a marked inhibitory effect on MAO-A in humans in vivo) produced negligible changes in trace amine excretion. In comparison to recent studies of individuals lacking the genes for MAO-A, MAO-B, or both MAO-A and MAO-B, the lack of change in trace amine excretion in individuals with a mutation affecting only MAO-A is in agreement with the observed lack of effect of clorgyline in the present study. Selegiline produced larger changes in trace amines-at least at the higher doses studied-than found in individuals lacking the gene for MAO-B, in agreement with other data suggesting a lesser selectivity for MAO-B inhibition when selegiline was given in doses higher than 10mg/day. Overall, trace amine elevations in individuals receiving the highest dose of deprenyl or receiving pargyline were approximately three to five-fold lower than the elevations observed in individuals lacking the genes for both MAO-A and MAO- B, suggesting that these drug doses yield incomplete inhibition of MAO-A and MAO-B.

AB - Marked, dose-dependent elevation in the urinary excretion of phenylethylamine, para-tyramine, and meta-tyramine were observed in depressed patients treated for three or more weeks with 10, 30, or 60mg/day of the partially-selective inhibitor of MAO-B, selegiline (l-deprenyl). In comparative studies with other, structurally similar acetylenic inhibitors of MAO, pargyline, an MAO-B > MAO-A inhibitor used in doses of 90mg/day for three or more weeks, produced elevations in these trace amines which were similar to those found with the highest dose of selegiline studied. Clorgyline, a selective inhibitor of MAO-A used in doses of 30mg/day for three or more weeks (a dose-time regimen previously reported to reduce urinary, plasma, and cerebrospinal fluid 3-methoxy-4- hydroxyphenylethyleneglycol (MHPG) > 80%, indicating a marked inhibitory effect on MAO-A in humans in vivo) produced negligible changes in trace amine excretion. In comparison to recent studies of individuals lacking the genes for MAO-A, MAO-B, or both MAO-A and MAO-B, the lack of change in trace amine excretion in individuals with a mutation affecting only MAO-A is in agreement with the observed lack of effect of clorgyline in the present study. Selegiline produced larger changes in trace amines-at least at the higher doses studied-than found in individuals lacking the gene for MAO-B, in agreement with other data suggesting a lesser selectivity for MAO-B inhibition when selegiline was given in doses higher than 10mg/day. Overall, trace amine elevations in individuals receiving the highest dose of deprenyl or receiving pargyline were approximately three to five-fold lower than the elevations observed in individuals lacking the genes for both MAO-A and MAO- B, suggesting that these drug doses yield incomplete inhibition of MAO-A and MAO-B.

UR - http://www.scopus.com/inward/record.url?scp=0031596683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031596683&partnerID=8YFLogxK

M3 - Article

SP - 39

EP - 48

JO - Journal of Neural Transmission, Supplement

JF - Journal of Neural Transmission, Supplement

SN - 0303-6995

IS - 52

ER -